Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
$854.99
$8.96(1.38%)
At close: 4:00 PM EST
$854.99
$8.96(1.38%)
Day’s Range― - ―
52-Week Range$510.06 - $934.62
Previous CloseN/A
Volume151.62K
Average Volume (3M)331.85K
Market Cap
$53.06B
Enterprise Value$31.60B
Total Cash (Recent Filing)$3.93B
Total Debt (Recent Filing)$43.15M
Price to Earnings (P/E)40.2
Beta0.21
Next Earnings
Feb 26, 2026EPS Estimate
6.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.18
Shares Outstanding61,568,928
10 Day Avg. Volume334,741
30 Day Avg. Volume331,849
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)6.70
Price to Sales (P/S)16.81
P/FCF Ratio-243.71
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue13.77
Enterprise Value/Gross Profit20.81
Enterprise Value/Ebitda49.33
Forecast
1Y Price Target
$1,033.47Price Target Upside20.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biotech GrowthVyvgart has been one of the best growth stories in all of biotech, offering some of the best growth in large-cap biotech.
Expansion OpportunitiesThere is significant opportunity to expand into additional indications with multiple shots on goal.
Financial PerformanceArgenx delivered a strong performance in the 3Q, with sales of $1.13 billion, up 96% year-over-year and 18% quarter-over-quarter.
Bears Say
Clinical RisksThere is some clinical risk ahead of upcoming readouts, and there is not high confidence that positive data will drive meaningful outperformance.
Discontinued StudiesThe phase 3 UplighTED studies evaluating efgartigimod in thyroid eye disease (TED) will be discontinued following a pre-specified futility analysis.
Valuation ConcernsThe valuation here feels stretched, and high expectations are already baked in.
Argenx Se News
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $510.06 and its highest was $934.62 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $53.06B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Feb 26, 2026 which is in 68 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Oct 30, 2025. The company reported $5.18 earnings per share for the quarter, beating the consensus estimate of $4.491 by $0.689.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 6.04.
How many shares outstanding does Argenx Se have?
Argenx Se has 61,568,928 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $5.18 in its last earnings report, beating expectations of $4.491. Following the earnings report the stock price went down -0.196%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,033.47 (20.88% Upside)
$1,033.47 (20.88% Upside)
Blogger Sentiment
Neutral
ARGX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 116.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.1%
Last 30 Days ▲ 10.0%
Last 30 Days ▲ 10.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.70%
12-Months-Change
Fundamentals
Return on Equity
24.75%
Trailing 12-Months
Asset Growth
49.60%
Trailing 12-Months
Company Description
Argenx Se
Argenx SE is a global biotechnology company focused on the development and commercialization of innovative therapies for the treatment of severe autoimmune diseases and cancer. The company specializes in harnessing the power of its proprietary antibody engineering technology to create unique therapeutic antibodies, including its lead product candidates, which target unmet medical needs in various sectors of medicine. Argenx operates primarily in the biopharmaceutical sector, with a strong emphasis on developing therapies that improve the lives of patients with complex diseases.
ARGX Company Deck
ARGX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and successful product launches, particularly the PFS, alongside significant pipeline progress. However, there were setbacks in certain pipeline developments and increased operating expenses. Despite this, the positives of revenue growth and successful commercial strategies outweigh the negatives.View all ARGX earnings summariesARGX Stock 12 Month Forecast
Average Price Target
$1,033.47
▲(20.88% Upside)
Technical Analysis
Ownership Overview
―
Insiders
18.95% Mutual Funds
17.59% Other Institutional Investors
62.28% Public Companies and Individual Investors